Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy have entered into a clinical collaboration agreement that providesthem to undertake clinical evaluation of novel combination regimens within the field of immuno-oncology.    The goal of the partnership is to design innovative studies that have the potential to address cancers with high unmet need. The initial trial under consideration between Inovio and the Parker Institute would address muscle invasive bladder canc...